Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
NCT: NCT07526545 · NOT_YET_RECRUITING
Brief Summary
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Frequently Asked Questions
What is Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial?
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial is a clinical trial registered under NCT07526545. Current status: NOT_YET_RECRUITING.
What is the status of NCT07526545?
The current status of NCT07526545 (Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial) is: NOT_YET_RECRUITING.
When did Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial start?
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial started on 2026-05-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.